The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution.
The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while increasing fat loss.
As the lead investigator for the trial, Dr. Rosenstock stated in the Regeneron press release: “These complete 26-week COURAGE results demonstrate a meaningful opportunity to preserve muscle mass while enhancing fat loss.”
Also noted: “Numerical improvements in metabolic and lipid parameters, secondary and exploratory endpoints, were seen across all treatment groups, including improvements in waist circumference, blood pressure, cholesterol, triglycerides and A1C.”
Read the full press release: https://investor.regeneron.com/news-releases/news-release-details/results-phase-2-courage-trial-demonstrating-potential-improve
